noscript

News and Announcements

OncoSil Medical Annual Report 2016

  • Published September 16, 2016 11:29AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

12th September 2016, ASX Announcement

FY16 Achievements Delivered

September 2015 

Submission of CE Mark application for OncoSil™

October 2015

OncoSil™ CE Mark application granted Fast Track review status

December 2015

Investigational Device Exemption (IDE) submitted to the U.S. FDA for OncoPac-1 clinical study

January 2016

Chris Roberts appointed Independent Non-Executive Director

February 2016

$10 million private placement to Regal Funds Management

March-April 2016 

Q-Submissions meeting with FDA

Responses to CE Mark and FDA questions

May 2016 

OncoSil Medical completes hiring of senior management for Leadership team

To view the full announcement, please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now